Arthneeti

Panacea Biotec Share Price & Earnings Call Analysis

₹334.75+2.14% today
Market cap
₹2,050 Cr
ROE
-2.42%
Price to sales
3.04
Debt to equity
0.03
52W high / low
₹608 / ₹296
Sales growth (5Y)
0.47%
EBITDA margin
0.33%
Net profit margin
-4.22%
Promoter holding
72.48%
Sales (last year)
₹673 Cr

Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Panacea Biotec rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Panacea Biotec.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Panacea Biotec

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Panacea Biotec

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +115.20128.93129.19143.02150.50136.46115.72147.35163.49132.53166.70141.13165.19
Expenses +123.84134.60139.50146.58150.65142.50129.71140.35155.53159.41167.88158.92153.45
Operating Profit-8.64-5.67-10.31-3.56-0.15-6.04-13.997.007.96-26.88-1.18-17.7911.74
OPM %-7.50%-4.40%-7.98%-2.49%-0.10%-4.43%-12.09%4.75%4.87%-20.28%-0.71%-12.61%7.11%
Other Income +41.7134.4433.826.008.4613.556.547.426.3936.3016.999.105.05
Interest0.961.051.000.910.850.820.870.980.991.040.862.141.85
Depreciation9.679.519.489.319.118.818.738.688.988.428.398.348.45
Profit before tax22.4418.2113.03-7.78-1.65-2.12-17.054.764.38-0.046.56-19.176.49
Tax %13.68%169.63%15.73%6.56%33.33%-6.13%-6.86%1.05%-1.37%4,875.00%39.63%-26.92%40.06%
Net Profit +19.37-12.6810.98-8.29-2.20-1.99-15.884.714.44-1.993.96-14.013.89
EPS in Rs3.16-2.071.79-1.35-0.37-0.32-2.580.780.74-0.310.66-2.270.65

Financials of Panacea Biotec

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +510687653544593457544625661460559559606
Expenses +582643541505509591484548674558579584640
Operating Profit-72441123984-1346077-13-98-20-25-34
OPM %-14%6%17%7%14%-29%11%12%-2%-21%-4%-4%-6%
Other Income +1832870628338-2191,687154625567
Interest1501051271011011051741851814446
Depreciation71677368575443464439373534
Profit before tax-111-99-19-67-6645-178-1461,449131-8-6
Tax %2%3%10%-16%15%17%9%1%26%363%201%10%
Net Profit +-113-108-21-56-7638-194-1481,078-34-2-9-8
EPS in Rs-18.29-17.38-2.98-8.89-12.076.15-31.69-24.09175.91-5.42-0.19-1.37-1.27
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Panacea Biotec

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital6666666666666
Reserves507449426350303344193-235871837836829820
Borrowings +1,0601,1111,1059949416467428203420212223
Other Liabilities +371364317440349379449587848407378433405
Total Liabilities1,9431,9301,8541,7891,5981,3761,3901,1781,7591,2711,2411,2901,254
Fixed Assets +1,2761,1441,0711,001949806657609622600582567594
CWIP17215516130402324341742102128110
Investments16159775605134033
Other Assets +4796166147506025427035341,114615517592547
Total Assets1,9431,9301,8541,7891,5981,3761,3901,1781,7591,2711,2411,2901,254

Financials of Panacea Biotec

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +543791131118105-30107-108-422-0-27
Cash from Investing Activity +-38-3716-2655-6-35-481,2834301065
Cash from Financing Activity +-30-1-117-107-164-10191-47-1,176-18-3-3
Net Cash Flow-14-1-10-29-22612-2-10735
Free Cash Flow33085107103100-2189-119-424-71-77
CFO/OP-78%96%64%320%146%-77%-36%141%-2,235%429%-12%108%

Financials of Panacea Biotec

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days685279958471464945483747
Inventory Days375404516770651173344311296292282391
Days Payable430272318607540572463440327256244413
Cash Conversion Cycle13184278259195-328-73-8014837625
Working Capital Days-343-12627-46-96-36393-43-229-5-244
ROCE %-8%0%4%2%3%-16%5%5%-6%-10%-4%-5%
16out of 100

Momentum score · price trend

16 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,908 stocks
Last 12 months−22.5%32%
Last 6 months−9.7%38%
Last 3 months−20.2%18%

The price is 44.9% below its all-time high of ₹607.75 (9 Jun 2026). Stocks more than 20% below their peak have their score halved, so 32 became 16.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,908 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Panacea Biotec: 0.4 × 32 + 0.4 × 38 + 0.2 × 18 = 32, halved to 16 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 3 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Remus Pharmaceuticals (Q2 FY27)

    Standalone Revenue (H1 FY27 vs H1 FY26):** ₹62.08 Cr vs ₹46.85 Cr, growth of 32.51% . Key results statement takeaways from Remus Pharmaceuticals Ltd's Q2 FY27 e

  • Amrutanjan Healt (Q2 FY27)

    Q2 FY27 Net Sales:** ₹135.18 Crores, up 14.85% YoY (₹117.70 Crores in Q2 FY26) . Key investor presentation takeaways from Amrutanjan Health Care Ltd's Q2 FY27 i

  • Pfizer (Q2 FY27)

    Revenue from operations for the quarter ended September 30, 2026: ₹726.86 crore (Page 3). Key results statement takeaways from Pfizer Ltd's Q2 FY27 results stat

  • Aarti Drugs (Q2 FY27)

    826.2 Crore, up 27% YoY from Rs. Key investor presentation takeaways from Aarti Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peer

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals